Pharmacogenomics of suicidal events

Pharmacogenomics

Volumn 11, Issue 6, 2010, Pages 793-807

  Brent, David ^a   Melhem, Nadine ^a   Turecki, Gustavo ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antidepressant; Depression; Genetics; Pharmacogenomics; Suicidal ideation; Suicide; Treatment

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESCITALOPRAM; FLUOXETINE; GLUTAMATE RECEPTOR; INTERLEUKIN 28; INTERLEUKIN 28 ALPHA RECEPTOR; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR TYPE 2; NORADRENALIN TRANSPORTER; NORTRIPTYLINE; PAPILIN; PAROXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG; VENLAFAXINE;

DEPRESSION; DNA POLYMORPHISM; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR DEPRESSION; NEUROTRANSMISSION; PHARMACOGENOMICS; PHENOTYPE; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PHARMACOGENETICS; SUICIDE; SUICIDE ATTEMPT;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SUICIDE; SUICIDE, ATTEMPTED;

EID: 77952893653     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.64     Document Type: Review

References (99)

1. Teicher MH, Glod CA, Cole JO: Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 8, 186-212 (1993).
2. Healy D, Whitaker C: Antidepressants and suicide: risk-beneft conundrums. J. Psychiatry Neurosci. 28, 331-337 (2003).
3. Olfson M, Marcus SC, Shaffer D: Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch. Gen. Psychiatry 63, 865-872 (2006).
4. Stone M, Laughren T, Jones ML et al.: Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 11, 339-342 (2009).
5. Gibbons RD, Brown CH, Hur K et al.: Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am. J. Psychiatry 164, 1356-1363 (2007).
6. Gibbons R, Brown CH, Hur K, Marcus S, Bhaumik DK, Mann JJ: The relationship between antidepressants and suicide: results of ana lysis of the Veterans Health Administration datasets. Am. J. Psychiatry 164, 1044-1049 (2007).
7. Olfson M, Shaffer D, Marcus SC, Greenberg T: Relationship between antidepressant medication treatment and suicide in adolescents. Arch. Gen. Psychiatry 60, 978-982 (2003).
8. Gibbons RD, Hur K, Bhaumik DK, Mann JJ: The relationship between antidepressant medication use and rate of suicide. Arch. Gen. Psychiatry 62, 165-172 (2005).
9. Ludwig J, Marcotte DE, Norberg K: Anti-depressants and suicide. J. Health Economics 28, 659-676 (2009).
10. Posner K, Oquendo M, Stanley B, Davies M, Gould M: Columbia Classifcation Algorithm of Suicide Assessment (C-CASA): classifcation of suicidal events in the FDA's pediatric suicidal risk ana lysis of antidepressants. Am. J. Psychiatry 164, 1035-1043 (2007).
11. Libby AM, Orton HD, Valuck RJ: Persisting decline in depression treatment after FDA warnings. Arch. Gen. Psychiatry 66, 633-639 (2009).
12. Zisook S, Trivedi MH, Warden D et al.: Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J. Affect. Disord. 117, 63-73 (2009).
13. Perlis RH, Purcell S, Fava M et al.: Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element bind protein in the STAR*D study. Arch. Gen. Psychiatry 64, 689-697 (2007).
14. Perroud N, Aitchison KJ, Uher R et al.: Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34, 2517-2528 (2009).
15. Brent DA, Emslie G, Clarke G et al.: Predictors of spontaneous and systematically assessed suicidal adverse events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Study. Am. J. Psychiatry 166, 418-426 (2009).
16. Vitiello B, Silva SG, Rohde P et al.: Suicidal events in the Treatment of Adolescents with Depression Study (TADS). J. Clin. Psychiatry 70, 741-747 (2009).
17. Perlis RH, Beasley CM Jr, Wines JD Jr et al.: Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fuoxetine for major depressive episodes. Psychother. Psychosom. 76, 40-46 (2007).
18. Laje G, Paddock S, Manji H et al.: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am. J. Psychiatry 164, 1530-1538 (2007).
19. Seemuller F, Riedel M, Obermeier M et al.: The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int. J. Neuropsychopharmacol. 12, 181-189 (2009).
20. Laje G, Perlis RH, Rush AJ, McMahon FJ: Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr. Serv. 60, 1446-1457 (2009).
21. Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ: Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet. Genomics 19, 666-674 (2009).
22. Menke A, Lucae S, Kloiber S et al.: Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am. J. Psychiatry 165, 917-918 (2008).
23. Brent DA, Melhem N, Ferrell R et al.: Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am. J. Psychiatry 167(2), 190-197 (2010).
24. Perlis RH, Purcell S, Fagerness J et al.: Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol. Psychiatry 62, 536-540 (2007).
25. Dwivedi Y, Rao JS, Rizavi HS et al.: Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide sujects. Arch. Gen. Psychiatry 60, 273-282 (2003).
26. Odagaki Y, Garcia-Sevilla JA, Huguelet P, La Harpe R, Koyama T, Guimon J: Cyclic AMP-mediated signaling components are upregulated in the prefrontal cortex of depressed suicide victims. Brain Res. 898, 224-231 (2001).
27. Young LG, Bezchlibnyk YB, Chen B, Wang JF, MacQueen GM: Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide and drug treatment. Biol. Psychiatry 55, 570-577 (2004).
28. Rush AJ, Bernstein IH, Trivedi MH et al.: An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol. Psychiatry 59, 493-501 (2006).
29. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA: Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74(1), 106-120 (2004).
30. Hambleton RK, Swaminathan H, Rogert HJ: Fundamentals of Item Response Theory. Sage Press, CA, USA (1991).
31. Perroud N, Uher R, Marusic A et al.: Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med. 7, 60 (2009).
32. Bridge J, Iyengar S, Salary CB et al.: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-ana lysis of randomized controlled trials. J. Am. Med. Assoc. 297, 1683-1696 (2007).
33. Bridge J, Barbe R P, Birmaher B, Kolko DJ, Brent DA: Emergent suicidality in a clinical psychotherapy trial for adolescent depression. Am. J. Psychiatry 162, 2173-2175 (2005).
34. Mann JJ, Waternaux C, Haas GL, Malone KM: Toward a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry 156(2), 181-189 (1999).
35. Brent DA, Mann JJ: Family genetic studies, suicide, and suicidal behavior. Am. J. Med. Genet. 133C, 13-24 (2005).
36. Mann JJ: Neurobiology of suicidal behavior. Nat. Rev. Neurosci. 4, 819-828 (2003).
37. Brent DA, Oquendo MA, Birmaher B et al.: Peripubertal suicide attempts in offspring of suicide attempters with siblings concordant for suicidal behavior. Am. J. Psychiatry 160(8), 1486-1493 (2003).
38. McGirr AM, Alda M, Seguis M, Cabot S, Lesage A, Turecki G: Familial aggregation of suicide is explained by cluster B traits: a three-group family study of suicide controlling for major depressive disorder. Am. J. Psychiatry 166, 1124-1134 (2009).
39. Melhem NM, Brent DA, Ziegler M et al.: Familial pathways to early-onset suicidal behavior: familial and individual antecedents of suicidal behavior. Am. J. Psychiatry 164, 1364-1370 (2007).
40. Meltzer HY, Alphs L, Green AI et al.: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82-91 (2003).
41. Akiskal H, Benazzi F: Does the FDA proposed list of possible correlates of suicidality associated with antidepressants apply to an adult private practice population? J. Affect. Disord. 94, 105-110 (2006).
42. Hansen L, Kingdom D: Akathisia as a risk factor for suicide. Br. J. Psychiatry 188, 192-195 (2006).
43. Smith EG: Association between antidepressant half-life and the risk of suicidal ideation or behavior among children and adolescents: confrmatory ana lysis and research implications. J. Affect. Disord. 114, 143-148 (2009).
44. Lotrich FE, Pollock BG, Kirshner M, Ferrell RF, Reynolds CF 3rd: Serotonin transporter genotype interacts with paroxetine plasma levels to infuence depression treatment response in geriatric patients. J. Psychiatry Neurosci. 33, 123-130 (2008).
45. Lotrich FE, Bies RR, Smith GS, Pollock BG: Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J. Psychopharmacol. 20(4 Suppl.), 33-40 (2006).
46. Zackrisson AL, Lindblom B, Ahlner J: High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicatin ultrarapid metabolism among suicide cases. Clin. Pharmacol. Ther. DOI:10.1038/clpt.2009.216 (2009) (Epub ahead of print).
47. Kawanishi C, Lundgren S, Agren H, Bertilsson L: Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. 59, 803-807 (2004).
48. Brent DA: In search of endophenotypes for suicidal behavior. Am. J. Psychiatry 166, 1087-1089 (2009).
49. Mann JJ, Arrango VA, Avenevoli S et al.: Candidate endophenotypes for genetic studies of suicidal behavior. Biol. Psychiatry 65, 556-563 (2009).
50. Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 352, 1754-1755 (1998).
51. Tsai S-J: Possible involvement of the BNDF-dependent pathway in treatment-emergent suicidality or decreased response to antidepressants. Med. Hypotheses 65, 942-946 (2005).
52. Dwivedi Y: Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr. Disord. Treat. 5, 433-449 (2009).
53. Sarchiapone M, Carli V, Roy A et al.: Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. Neuropsychobiology 57, 139-145 (2008).
54. Kim B, Kim CY, Hong JP, Lee C, Joo YH: Brain-derived neurotrophic factor Val/Met polymorphism and bipolar disorder. Association of the Met allele with suicidal behavior of bipolar patients. Neuropsychobiology 58, 97-103 (2008).
55. Wagner S, Baskaya O, Dahmen N, Lieb K, Tadic A: Modulatory role of the brain-derived neurotrophic factor ValMet polymorphism on the effects of serious life events on impulsive aggression in borderline personality disorder. Genes Brain Behav. 9, 97-102 (2010).
56. Henningsson S, Borg J, Lundberg J et al.: Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men. Biol. Psychiatry 66, 477-485 (2009).
57. Ernst C, Mechawar N, Turecki G: Suicide neurobiology. Progr. Neurobiol. 89, 315-333 (2009).
58. Kohli MA, Salyakina D, Pfennig A et al.: Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch. Gen. Psychiatry 67, E1-E12 (2010).
59. Pandey GN, Dwivedi Y: Noradrenergic function in suicide. Arch. Suicide Res. 11, 235-246 (2007).
60. Sequeira A, Mamdani F, Lalovic A et al.: a2A adrenergic receptor gene and suicide. Psychiatry Res. 125, 87-93 (2004).
61. Palucha A, Pilc A: The involvement of glutamate in the pathophysiology of depression. Drug News Perspect. 18, 262-268 (2005).
62. Martinez-Turrillas R, Frechilla D, Del Río J: Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 43(8), 1230-1237 (2002).
63. Barbon A, Popoli M, La Via L et al.: Regulation of editing and expression of glutamate a-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol. Psychiatry 59, 713-720 (2006).
64. Price RB, Nock MK, Charney DS, Mathew SJ: Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66, 522-526 (2009).
65. Sequeira A, Mamdani F, Ernst C et al.: Global brain gene expression ana lysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 4, E6585 (2009).
66. Pace TW, Miller AH: Cytokines and glucocorticoid receptor signaling. Ann. NY Acad. Sci. 1179, 86-105 (2009).
67. Anisman H, Merali Z: Cytokines, stress and depressive illness: brain-immune interactions. Ann. Med. 35, 2-11 (2003).
68. Lindqvist D, Janelidze S, Hagell P et al.: Interleukin-6 is elevated in the cerebrospinal fuid of suicide attempters and related to symptom severity. Biol. Psychiatry 66, 287-292 (2009).
69. Saiz PA, Garcia-Portilla P, Paredes B et al.: Association study of the interleukin-1 gene complex and tumor necrosis factor a gene with suicide attempts. Psychiatric Genet. 18, 147-150 (2008).
70. Omrani MD, Bushehri B, Bagheri M, Salari-Lak S, Alipour A, Anoshae MR et al.: Role of IL-10-1-82, IFN-g+874, and TNF-a-308 genes polymorphisms in suicidal behavior. Arch. Suicide Res. 13, 330-339 (2009).
71. Ising M, Depping A-M, Siebertz A et al.: Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur. J. Neuroscience 28, 389-398 (2008).
72. Scammell JG, Hubler TR, Denny WB, Valentine DL: Organization of the human FK506-binding immunophilin FKBP52 protein gene (FKBP4). Genomics 81, 640-643 (2003).
73. Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG: Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 141, 4107-4113 (2000).
74. Mann JJ, Currier D: A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch. Suicide Res. 11, 3-16 (2007).
75. Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch M-A: Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology DOI:10.1038/npp.2009.236 (2010) (Epub ahead of print).
76. Binder EB, Bradley RG, Liu W et al.: Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. J. Am. Med. Assoc. 19, 1291-1305 (2008).
77. Binder EB: The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34, S186-S195 (2009).
78. Zobel A, Schuhmacher A, Jessen F, Hofels S, von Widdern O, Metten M et al.: DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int. J. Neuropsychopharmacol. 5, 1-12 (2010).
79. Currier D, Mann JJ: Stress, genes and the biology of suicidal behavior. Psychiatr. Clin. North Am. 31, 247-269 (2008).
80. Schosser A, Kasper S: The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int. Clin. Psychopharmacol. 24, 277-288 (2009).
81. Joyce PR, Mulder RT, Luty SE et al.: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein b3 subunit as predictors of response to fuoxetine and nortriptyline. Int. J. Neuropsychopharmacol. 6, 339-3466 (2003).
82. Mulder RT, Watkins W GA, Joyce PR, Luty SE: Age may affect response to antidepressants with serotonergic and noradrenergic actions. J. Affect. Disord. 76, 143-149 (2003).
83. Caspi A, Sugden K, Mofftt TE et al.: Infuence of life stress on depression: moderation by a polymorphism in the 5-HT gene. Science 301, 386-389 (2003).
84. Barbe R P, Bridge J, Birmaher B, Kolko DJ, Brent DA: Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. J. Clin. Psychiatry 65(1), 77-83 (2004).
85. Asarnow JR, Emslie G, Clarke G et al.: Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J. Am. Acad. Child Adolesc. Psychiatr. 48, 330-339 (2009).
86. Nemeroff CB, Heim CM, Thase ME et al.: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc. Natl Acad. Sci. USA 100(24), 14293-14296 (2003).
87. Kaufman J, Yang BZ, Douglas-Palumberi H et al.: Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifers of depression in children. Biol. Psychiatry 59(8), 673-680 (2006).
88. Roy A: Self-rated childhood emotional neglect and CSF monoamine indices in abstinent cocaine-abusing adults: possible implications for suicidal behavior. Psychiatry Res. 112, 69-75 (2009).
89. Brunner J, Bronisch T, Uhr M et al.: Proteomic ana lysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters. Eur. Arch. Psychiatr. Clin. Neurosci. 255, 438-440 (2005).
90. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, Liotta LA: CSF proteome: a protein repository for potential biomarker identifcation. Expert Rev. Proteomics 2(1), 57-70 (2005).
91. Marais L, Hattingh SM, Stein DJ, Daniels WM: A proteomic ana lysis of the ventral hippocampus of rats subjected to maternal separation and escitalopram treatment. Metab. Brain Dis. 24, 569-586 (2009).
92. Ernst C, Bureau A, Turecki G: Application of microarray outlier detection methodology to psychiatric research. BMC Psychiatry 8, 29 (2008).
93. Sequeira A, Turecki G: Genome wide gene expression studies in mood disorder. OMICS 10, 444-454 (2006).
94. McGowan PO, Sasaki A, Huang TC et al.: Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PLoS One 3, E2085 (2008).
95. Ernst C, Sequeira A, Klempan T, Ernst N, Ffrench-Mullen JM, Turecki G: Confrmation of region-specifc patterns of gene expression in the human brain. Neurogenetics 8, 219-224 (2007).
96. Leuchter AF, Cook IA, Hunter AM, Korb AS: A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin. Neurosci. 11, 435-446 (2009).
97. Licinio J, Dong C, Wong M-L: Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry 66, 488-497 (2009).
98. Vansteelandt S, Goetgeluk S, Lutz S et al.: On the adjustment for covariates in genetic association ana lysis: a novel, simple principle to infer direct causal effects. Genet. Epidemiol. 33, 394-405 (2009).
99. Lee AB, Luca D, Klei L, Devlin B, Roeder K: Discovering genetic ancestry using spectral graph theory. Genet. Epidemiol. 34(1), 51-59 (2010).